Clinical Trial

Inclisiran Effectiveness in China: a Pragmatic Randomized Trial

Study acronym: V-INVINCIBLE
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The current study will be conducted to evaluate the real-world effectiveness of inclisiran relative to standard of care (SoC) in Chinese patients with coronary heart disease (CHD), not only with the low-density lipoprotein cholesterol (LDL-C) change in 1 year, but also the LDL-C Test on Target for 1 year. This study further aims to assess the adherence, treatment patterns and satisfaction, and safety of inclisiran among Chinese patients.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-01-30 -> 2027-04-30 2026-05-30
minor Completion pushed: 2026-01-30 -> 2027-04-30 2026-05-30
Trial Details
NCT Number NCT06941792
Lead Sponsor Novartis Pharmaceuticals
Conditions Coronary Heart Disease
Enrollment 1,590 participants
Start Date 2025-06-17
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-29